Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for MediciNova Inc. (MNOV:NASDAQ), powered by AI.
MediciNova Inc. is currently trading at $1.31. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for MediciNova Inc. on Alpha Lenz.
MediciNova Inc.'s P/E ratio is -5.4.
“MediciNova Inc. trades at a P/E of -5.4 (undervalued) with modest ROE of -25.5%.”
Ask for details →MediciNova Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for unmet medical needs. The company's primary mission is to improve patient outcomes through innovative treatments that address diverse and challenging conditions, particularly those in the fields of neurology, respiratory, and liver diseases. MediciNova's pipeline includes several investigational drugs targeting neurological disorders such as multiple sclerosis and amyotrophic lateral sclerosis (ALS), as well as potential treatments for respiratory ailments and non-alcoholic steatohepatitis (NASH). Headquartered in California, MediciNova plays a significant role in advancing medical research and development. Its work contributes to critical sectors of the healthcare industry by aiming to bring new solutions to the market that address areas with few existing treatment options. As a participant in the global biopharmaceutical landscape, MediciNova collaborates with research institutions and industry partners, enhancing its ability to innovate and fulfill its commitment to improving lives through science.
“MediciNova Inc. trades at a P/E of -5.4 (undervalued) with modest ROE of -25.5%.”
Ask for details →MediciNova Inc. (ticker: MNOV) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 13 employees. Market cap is $64M.
The current price is $1.31 with a P/E ratio of -5.36x and P/B of 1.55x.
ROE is -25.50% and operating margin is -3242.47%. Annual revenue is $409,657.